Clinical Trials Logo

Filter by:
NCT ID: NCT00922597 Completed - Hemophilia A Clinical Trials

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

NO PEACKS
Start date: August 2008
Phase: N/A
Study type: Observational

The objective of this international post-marketing surveillance study is to collect data on the efficacy and safety of continuous infusion with KOGENATE Bayer in surgery.

NCT ID: NCT00910715 Completed - Clinical trials for Erythema Chronicum Migrans

Duration of Antibiotic Treatment of Erythema Migrans

Start date: June 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of 15-day versus 10-day doxycycline treatment in patients with erythema migrans.

NCT ID: NCT00904371 Completed - Hypertension Clinical Trials

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

Start date: December 2009
Phase: N/A
Study type: Observational

The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks. Further on, the study will evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.

NCT ID: NCT00903331 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

MUSIC
Start date: May 2009
Phase: Phase 2
Study type: Interventional

The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF). The main study objective is to demonstrate that macitentan positively affects the forced vital capacity (FVC) in comparison with placebo in patients with idiopathic pulmonary fibrosis (IPF). The secondary objectives are to evaluate the effect of macitentan on the time to disease worsening or death in patients with IPF, and to evaluate the benefit/risk profile of macitentan in the treatment of patients with IPF.

NCT ID: NCT00895674 Completed - Clinical trials for Carcinoma, Renal Cell

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Start date: July 2006
Phase: N/A
Study type: Observational

Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis. When this study has been started the standard therapy for patients has been cytokines, which might be accompanied by significant toxicities or might fail the therapeutic goal. In these cases sorafenib can be a feasible therapeutic option. This non-interventional study has been created and is being conducted to collect clinical data on the patients' therapy with sorafenib in an everyday treatment schedule. The main goal of this study focuses on patient characteristics and tumor status in RCC treated with sorafenib as well as the treatment duration and safety of sorafenib under everyday treatment conditions.

NCT ID: NCT00882453 Completed - Multiple Sclerosis Clinical Trials

Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

BEGIN
Start date: August 2006
Phase: N/A
Study type: Observational

The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients with recently diagnosed MS, and to obtain information on factors potentially influencing the patients' level of activity.

NCT ID: NCT00878475 Completed - Asthma Clinical Trials

Dyspnea and Biomarkers in a Prehospital Setting

Start date: January 2005
Phase: N/A
Study type: Observational

In patients presenting with acute dyspnea in a pre-hospital setting, the early and correct diagnosis may present a significant clinical challenge. Physical examination, chest radiography, electrocardiography, and standard biological tests often fail to accurately differentiate heart failure (HF) from pulmonary causes of dyspnea. Timely differentiation of HF from other causes of dyspnea may permit the early institution of appropriate medical therapy. Brain natriuretic peptide (BNP) and amino-terminal pro-brain natriuretic peptide (NT-proBNP) have been proposed as early markers of HF and demonstrated to be useful for diagnosing and excluding HF in the emergency department. A combination of BNP or NT-proBNP testing and standard clinical assessment has been suggested to be superior to either tool used in isolation. Some previous studies have also suggested that quantitative capnometry (QC) may be useful in differentiating between cardiac and obstructive causes of respiratory distress. Therefore, the investigators hypothesized that a new combination of NT-proBNP testing, standard clinical assessment, and partial pressure of end-tidal CO2 (PetCO2) would optimize evaluation and differentiation of acute dyspnea in a pre-hospital setting. The aim of this study was to determine the accuracy of combination of QC, NT-proBNP, and clinical assessment in differentiating acute HF from obstructive pulmonary disease (COPD/asthma) as a cause of acute dyspnea in pre-hospital emergency setting.

NCT ID: NCT00874926 Completed - Hemophilia A Clinical Trials

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Start date: June 2008
Phase: N/A
Study type: Observational

The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of patients with haemophilia A under daily-life treatment conditions.

NCT ID: NCT00868491 Completed - Clinical trials for Head and Neck Cancer

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and toxicity of docetaxel/cisplatin/5-fluorouracil induction chemotherapy (4 cycles) followed by concomitant chemoradiation with cetuximab and weekly cisplatin in patients with inoperable squamous cell carcinoma of the head and neck.

NCT ID: NCT00864851 Completed - Fabry Disease Clinical Trials

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

Start date: December 29, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and effectiveness of various doses of Replagal in patients with cardiomyopathy due to Fabry disease.